Strategic Alliance With Abbott On Drug And Biomarker Development Candidates From China

< BACK TO RESEARCH starstarstarstarstar   Science - Research Press Release
14th May 2009, 11:16am - Views: 333





Science Research HUYA Bioscience International 1 image





Strategic Alliance With Abbott on Drug and Biomarker Development Candidates From China


SAN DIEGO, May 14 /PRNewswire-AsiaNet/ --


          Collaboration will leverage HUYA's growing Chinese bioscience

                                   network


    HUYA Bioscience International, a leader in US/China pharmaceutical

co-development, today announced an agreement with Abbott to identify and

pursue proprietary preclinical and clinical drug candidates that originate in

China.


    Abbott will gain access to HUYA's growing Chinese bioscience network

comprising premier companies, universities, government research institutions

and bioparks throughout the country. HUYA has agreements in place with many

of these organizations whereby HUYA has ongoing exclusive access to compounds

and biologics in a variety of indications. HUYA is currently evaluating and

following the progress of more than 600 lead, preclinical and clinical drug

candidates.


    "China has an extremely rich pool of drug candidates, which we are able

to tap through our extensive network of partners," said Mireille Gingras,

PhD, President and CEO of HUYA. "We've been effective in leveraging those

relationships to the mutual benefit of our partners in the West and in China,

and we're looking forward to a productive collaboration with Abbott."


    HUYA's model is based on long-term relationships with its Chinese

partners and this provides a continuous source of compounds, unlike a single

compound strategy. Once a compound is licensed, the ongoing exchange of

expertise and data lowers risk and facilitates rapid and efficient clinical

development in both China and the West.


    HUYA currently has two clinical stage drugs licensed from China in the

therapeutic areas of Cardiovascular and Oncology for development in the West.


    HUYA's innovative model benefits partners in the West and China


    HUYA was one of the first companies to recognize China's potential to

help meet the global need for pre-clinical and clinical stage compounds for

the drug development process. HUYA identifies and licenses highly promising

pre-clinical and clinical stage compounds in China and provides access to

those compounds to partners in the West. Likewise, HUYA provides a valuable

bridge to Western development for its partners in China. HUYA's Chinese

partners retain development and marketing rights in China with the

expectation that both parties will benefit from the research and development

collaboration.


    One of the key differentiators of HUYA's approach is the assembly of a

high-level team of scientific and clinical advisors for each new compound.

The team collaborates with its Chinese partners to discuss and design

pre-clinical tests and clinical trials as the compounds enter the U.S.

development process, speeding the process and mitigating risk. HUYA's global

team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD,

Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel,

MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and

Science Research HUYA Bioscience International 2 image

Michael Robertson, MD.


    "HUYA has forged highly productive relationships with its Chinese

partners, which sets up the potential for clinical development and new

treatment options in several diseases," said Eric Topol, Chief Academic

Officer, Scripps Health, San Diego, CA.


    About HUYA

    HUYA is a leader in U.S./China pharmaceutical co-development with four

strategic offices in China, a broad Chinese compound portfolio, and a

significant number of exclusive agreements with premier Chinese biotech

centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai.



    USA:                                 China:

    Jan Tuttleman, PhD                   Li Zhu, PhD

    Vice President, Marketing            VP China Operations

    HUYA Bioscience International, LLC   HUYA Bioscience International, LLC     (858) 798-8800                       86

(21) 51323312

    jtuttleman@huyabio.com               lzhu@huyabio.com


    Media Contact:


    Juliet Travis

    (510) 452-3771

    juliet@travispr.com



SOURCE: HUYA Bioscience International


    CONTACT: USA, 

             Jan Tuttleman, PhD, Vice President, Marketing,

             +1-858-798-8800, 

             jtuttleman@huyabio.com, or 


             China, 

             Li Zhu, PhD, VP China Operations, 

             86 (21) 51323312, 

             lzhu@huyabio.com, both of HUYA Bioscience International; or 


             Media, 

             Juliet Travis, 

             +1-510-452-3771, 

             juliet@travispr.com, for HUYA Bioscience International


To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article